No summary available
No summary available
No summary available
No summary available
CMS released a new infographic and companion chartbook examining monitoring data from Medicaid section 1115 Substance Use Disorder (SUD) and Serious Mental Illness (SMI) demonstrations. The resources highlight trends in treatment access, provider availability, and care outcomes, offering states opportunities to benchmark their demonstration progress.
A senior adviser at the Veterans Health Administration said this month that as many as 2.1 million veterans with conditions like post-traumatic stress disorder (PTSD) or depression could be candidates for psychedelic therapies, but cautioned that the VA would likely treat only “four digits worth of patients” in the first year after any FDA approval as it manages supply and safety.
CDC reported a provisional 2025 age-adjusted death rate of 689.2 deaths per 100,000 population, the lowest ever reported death rate and 4.6% below the final 2024 rate of 722.1 deaths per 100,000 population.
These findings highlight opportunities to strengthen sustained engagement with evidence-based treatment and underscore the need for care models that better support patients following opioid UDT, including timely MOUD use and adherence support.
Available data, while limited, may indicate increased maintenance in SUD treatment for long-acting stimulants, and there is insufficient data to support the efficacy of non-stimulants for ADHD treatment in SUD patients.
National declines in BZD prescription fills and total dose dispensed over the past decade may indicate greater caution or selectiveness in BZD dispensing, potentially related to safety considerations and drug labeling changes.
This survey sought to understand MAUD awareness and attitudes among the general public.
HHS recently announced the 2026 Update to the National Plan to Address Alzheimer’s Disease and Related Dementias, taking Department-wide actions to guide coordinated federal action on dementia risk reduction, research and innovation, care, and support for people living with dementia and their families.
The clinical pearls session is highly anticipated each year at the Annual Meeting, and the Program Committee is once again seeking your submissions! Please share your unique patient cases and/or clinical challenges for consideration by the Jan. 7, 2027 deadline. #psychpharm #annualmeeting #louisville #AAPP2027
Plans are underway for our 30th Annual Meeting, taking place April 4-7, 2027, in Louisville, Kentucky! We can't wait to host in a new city and to bring you the latest updates in psychopharmacology education. Save the date and plan to join us! #psychpharm #annualmeeting #louisville #AAPP2027
No summary available
This research provides meaningful insight that may further support existing or novel programming in prisons to meet individuals’ needs.
Interventions should consider addressing both substances, particularly co-use, given related risks.
These findings demonstrate that integrating principles of contingency management may increase engagement with a care navigator but may not increase linkage to treatment for methamphetamine use disorder.
These findings may be useful for health systems to guide decisions, while considering budget and capacity, on the modality and intensity of cessation interventions to adopt.
Truth Initiative provides a national youth vaping prevention curriculum.
The street drug has been linked to at least 55 deaths nationally from 2025 to 2026.
Vuse vapes, in flavors like peach and berry, hit market after agency softened its enforcement stance.
These results suggest that people with ADHD have increased risk of mortality across all-cause, suicide, unintentional or intentional injury, and natural cause; and ADHD medication may reduce the risk of all-cause mortality among people with ADHD, underscoring importance of timely diagnosis and treatment.
Pain care for people with opioid use disorder (OUD) appears to be influenced by intersecting structural, social and clinical barriers, including socioeconomic disadvantage and stigma.
Alcohol ketoacidosis complicates alcohol-related ED presentations in 11–26% of cases. Diagnosis was infrequent and increased recognition of this pathology may improve the care of these patients.
Buprenorphine and methadone were associated with distinct physical, addiction-related and mental health profiles.